These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

790 related items for PubMed ID: 23040208

  • 1. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.
    Klotz LH, McNeill IY, Kebabdjian M, Zhang L, Chin JL, Canadian Urology Research Consortium.
    Eur Urol; 2013 May; 63(5):927-35. PubMed ID: 23040208
    [Abstract] [Full Text] [Related]

  • 2. Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy.
    Choo R, Lukka H, Cheung P, Corbett T, Briones-Urbina R, Vieth R, Ehrlich L, Kiss A, Danjoux C.
    Int J Radiat Oncol Biol Phys; 2013 Apr 01; 85(5):1239-45. PubMed ID: 23265571
    [Abstract] [Full Text] [Related]

  • 3. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial.
    Greenspan SL, Nelson JB, Trump DL, Resnick NM.
    Ann Intern Med; 2007 Mar 20; 146(6):416-24. PubMed ID: 17371886
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
    Emkey R, Delmas PD, Bolognese M, Borges JL, Cosman F, Ragi-Eis S, Recknor C, Zerbini CA, Neate C, Sedarati F, Epstein S.
    Clin Ther; 2009 Apr 20; 31(4):751-61. PubMed ID: 19446148
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of monthly ibandronate in men with low bone density.
    Orwoll ES, Binkley NC, Lewiecki EM, Gruntmanis U, Fries MA, Dasic G.
    Bone; 2010 Apr 20; 46(4):970-6. PubMed ID: 20060082
    [Abstract] [Full Text] [Related]

  • 6. Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy.
    Greenspan SL, Nelson JB, Trump DL, Wagner JM, Miller ME, Perera S, Resnick NM.
    J Clin Oncol; 2008 Sep 20; 26(27):4426-34. PubMed ID: 18802155
    [Abstract] [Full Text] [Related]

  • 7. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial.
    Chevrel G, Schott AM, Fontanges E, Charrin JE, Lina-Granade G, Duboeuf F, Garnero P, Arlot M, Raynal C, Meunier PJ.
    J Bone Miner Res; 2006 Feb 20; 21(2):300-6. PubMed ID: 16418786
    [Abstract] [Full Text] [Related]

  • 8. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.
    Lems WF, Lodder MC, Lips P, Bijlsma JW, Geusens P, Schrameijer N, van de Ven CM, Dijkmans BA.
    Osteoporos Int; 2006 Feb 20; 17(5):716-23. PubMed ID: 16463007
    [Abstract] [Full Text] [Related]

  • 9. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.
    Stoch SA, Saag KG, Greenwald M, Sebba AI, Cohen S, Verbruggen N, Giezek H, West J, Schnitzer TJ.
    J Rheumatol; 2009 Aug 20; 36(8):1705-14. PubMed ID: 19487264
    [Abstract] [Full Text] [Related]

  • 10. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.
    Khan AA, Bilezikian JP, Kung AW, Ahmed MM, Dubois SJ, Ho AY, Schussheim D, Rubin MR, Shaikh AM, Silverberg SJ, Standish TI, Syed Z, Syed ZA.
    J Clin Endocrinol Metab; 2004 Jul 20; 89(7):3319-25. PubMed ID: 15240609
    [Abstract] [Full Text] [Related]

  • 11. Oral bisphosphonate prevents bone loss in androgen deprivation therapy for nonmetastatic prostate cancer.
    Kawahara T, Kobayashi T, Nishizawa K, Kobori G, Mitsumori K, Ogura K.
    Hinyokika Kiyo; 2008 Apr 20; 54(4):261-6. PubMed ID: 18516917
    [Abstract] [Full Text] [Related]

  • 12. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis.
    Rizzoli R, Greenspan SL, Bone G, Schnitzer TJ, Watts NB, Adami S, Foldes AJ, Roux C, Levine MA, Uebelhart B, Santora AC, Kaur A, Peverly CA, Orloff JJ, Alendronate Once-Weekly Study Group.
    J Bone Miner Res; 2002 Nov 20; 17(11):1988-96. PubMed ID: 12412806
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.
    Orwoll ES, Miller PD, Adachi JD, Brown J, Adler RA, Kendler D, Bucci-Rechtweg C, Readie A, Mesenbrink P, Weinstein RS.
    J Bone Miner Res; 2010 Oct 20; 25(10):2239-50. PubMed ID: 20499357
    [Abstract] [Full Text] [Related]

  • 14. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.
    Bone; 2007 Jul 20; 41(1):122-8. PubMed ID: 17468062
    [Abstract] [Full Text] [Related]

  • 15. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.
    Planas J, Trilla E, Raventós C, Cecchini L, Orsola A, Salvador C, Placer J, Encabo G, Morote J.
    BJU Int; 2009 Dec 20; 104(11):1637-40. PubMed ID: 19549260
    [Abstract] [Full Text] [Related]

  • 16. Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss.
    Choi HJ, Im JA, Kim SH.
    Maturitas; 2008 Jun 20; 60(2):170-6. PubMed ID: 18572334
    [Abstract] [Full Text] [Related]

  • 17. Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo-controlled study.
    Tee SI, Yosipovitch G, Chan YC, Chua SH, Koh ET, Chan YH, Tan SS, Tsou IY, Tan SH.
    Arch Dermatol; 2012 Mar 20; 148(3):307-14. PubMed ID: 22105813
    [Abstract] [Full Text] [Related]

  • 18. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group.
    Ravn P, Clemmesen B, Christiansen C.
    Bone; 1999 Mar 20; 24(3):237-44. PubMed ID: 10071916
    [Abstract] [Full Text] [Related]

  • 19. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM, Torréns JI, Harding P, Howard RS, Duncan WE, McLeod DG.
    Prostate Cancer Prostatic Dis; 2002 Mar 20; 5(4):304-10. PubMed ID: 12627216
    [Abstract] [Full Text] [Related]

  • 20. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial.
    Cheung AM, Tile L, Cardew S, Pruthi S, Robbins J, Tomlinson G, Kapral MK, Khosla S, Majumdar S, Erlandson M, Scher J, Hu H, Demaras A, Lickley L, Bordeleau L, Elser C, Ingle J, Richardson H, Goss PE.
    Lancet Oncol; 2012 Mar 20; 13(3):275-84. PubMed ID: 22318095
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.